Erratum: Frequent large germline HRPT2 deletions in a French National Cohort of patients with primary hyperparathyroidism (J Clin Endocrinol Metab (2013) 98 (E403-E408) DOI:10.1210/jc.2012-2789);Frequent large germline HRPT2 deletions in a french national cohort of patients with primary hyperparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 1766-

  Bricaire, Léopoldine ^a,b   Odou, Marie Françoise ^c,d   Cardot Bauters, Catherine ^c   Delemer, Brigitte ^e   North, Marie Odile ^f   Salenave, Sylvie ⁱ   Vezzosi, Delphine ^h   Kuhn, Jean Marc ^j   Murat, Arnaud ^k   Caron, Philippe ^h   Sadoul, Jean Louis ^o   Silve, Caroline ^i,p   Chanson, Philippe ^i,l   Barlier, Anne ^m,n   Clauser, Eric ^f,r   Porchet, Nicole ^c,d,q   Groussin, Lionel ^f,g,r,s  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIV LILLE   (France)

^e REIMS UNIVERSITY HOSPITAL   (France)

^f Institut National de la Santeet de la Recherche Me'Dicale Paris   (France)

^g Institut Cochin   (France)

^h CHU RANGUEIL   (France)

ⁱ BICÊTRE HOSPITAL   (France)

^j ROUEN UNIVERSITY HOSPITAL   (France)

^k CHU de Nantes   (France)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m AIX MARSEILLE UNIVERSITY   (France)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^p BICHAT HOSPITAL   (France)

^q Centre de Recherche J P Aubert   (France)

^r UNIVERSITÉ PARIS DESCARTES   (France)

^s Rue du Faubourg St Jacques   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA;

ADOLESCENT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA SEQUENCE; FEMALE; GENE; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HRPT2 GENE; HUMAN; HUMAN TISSUE; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

EID: 84873636808     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1580     Document Type: Erratum

References (27)

1. Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145-158.
2. Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 2010; 24(3):491-502.
3. Marsh DJ, Hahn MA, Howell VM, Gill AJ. Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. Expert Opin Med Diagn. 2007;1(3):377-392.
4. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. NEngl J Med. 2000;343(25):1863-1875.
5. Westin G, Bjö rklund P, Akerström G. Molecular genetics of parathyroid disease. World J Surg. 2009;33(11):2224-2233.
6. Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery. 1990;108(6):1006-1012; discussion 1012-1013.
7. Wassif WS, Farnebo F, Teh BT, et al. Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf). 1999;50(2):191-196.
8. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32(4):676-680.
9. Iacobone M, Barzon L, Porzionato A, et al. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery. 2007;142(6):984-991; discussion 984-991.
10. Bradley KJ, Hobbs MR, Buley ID, et al. Uterine tumours are a phenotypic manifestation of the hyperparathyroidism-jaw tumour syndrome. J Intern Med. 2005;257(1):18-26.
11. Teh BT, Farnebo F, Kristoffersson U, et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J Clin Endocrinol Metab. 1996;81(12):4204-4211.
12. Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010;31(3):295-307.
13. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, et al. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005;25(2):612-620.
14. Mosimann C, Hausmann G, Basler K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with β-catenin/Armadillo. Cell. 2006;125(2):327-341.
15. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Young A, Thakker RV. Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism. J Med Genet. 2005;42(8):e51.
16. Domingues R, Tomaz RA, Martins C, Nunes C, Bugalho MJ, Cavaco BM. Identification of the first germline HRPT2 whole-gene deletion in a patient with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2012;76(1):33-38.
17. Cascón A, Huarte-Mendicoa CV, Javier Leandro-García L, et al. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family. Genes Chromosomes Cancer. 2011;50(11):922-929.
18. Villablanca A, Calender A, Forsberg L, et al. Germline and de novo mutations in theHRPT2tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet. 2004;41(3):e32.
19. Pichardo-Lowden AR, Manni A, Saunders BD, Baker MJ. Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk. Endocr Pract. 2011;17(4):602-609.
20. Masi G, Barzon L, Iacobone M, et al. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer. 2008;15(4):1115-1126.
21. Frank-Raue K, Haag C, Schulze E, et al. CDC73-related hereditary hyperparathyroidism: five new mutations and the clinical spectrum. Eur J Endocrinol. 2011;165(3):477-483.
22. Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2009;70(4):533-538.
23. Caron P, Simonds WF, Maiza JC, et al. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation. Clin Endocrinol (Oxf). 2011;74(6):694-698.
24. Carlson D. Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Arch Pathol Lab Med. 2010;134(11):1639-1644.
25. Cetani F, Ambrogini E, Viacava P, et al. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol. 2007; 156(5):547-554.
26. Shattuck TM, Välimäki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349(18):1722-1729.
27. Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003;40(9):657-663.